Literature DB >> 8227404

Electron microscopic changes in Enterocytozoon bieneusi following treatment with albendazole.

C Blanshard1, D S Ellis, S P Dowell, G Tovey, B G Gazzard.   

Abstract

AIM: To identify and describe electron microscopic changes occurring in Enterocytozoon bieneusi in patients treated with albendazole.
METHODS: Eighteen HIV seropositive patients with E bieneusi infection of the small intestine were treated with albendazole 400 mg twice a day for one month. Duodenal biopsy specimens obtained before and at the end of treatment were examined electron microscopically by a pathologist who was unaware of the clinical response. A semiquantitative assessment of the parasite load and description of the parasite morphology was made.
RESULTS: A complete resolution of diarrhoea occurred in nine patients and a further three had a greater than 50% reduction in baseline stool frequency or volume. Three of the non-responders were also infected with cryptosporidium. There was a reduction in parasite load in those responding to treatment and an increase in abnormal forms in both responders and non-responders.
CONCLUSION: The clinical response to albendazole treatment seen in some patients with small intestine microsporidiosis may be due to damage to the developmental stages, causing a partial inhibition of parasite reproduction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227404      PMCID: PMC501614          DOI: 10.1136/jcp.46.10.898

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

1.  Cholangiopathy associated with Microsporidia infection of the common bile duct mucosa in a patient with HIV infection.

Authors:  L Beaugerie; M F Teilhac; A M Deluol; J Fritsch; P M Girard; W Rozenbaum; Y Le Quintrec; F P Chatelet
Journal:  Ann Intern Med       Date:  1992-09-01       Impact factor: 25.391

2.  The treatment of giardiasis with albendazole.

Authors:  S Di Rosa; M Affronti; R Malta; M Scardavi; L Vassallo; C Occhino; A Maggio; F Savalli; G B Rini
Journal:  J Chemother       Date:  1989-07       Impact factor: 1.714

3.  Microsporidiosis in HIV-1-infected individuals.

Authors:  C Blanshard; B G Gazzard
Journal:  Lancet       Date:  1991-06-15       Impact factor: 79.321

4.  Clinical significance of small-intestinal microsporidiosis in HIV-1-infected individuals.

Authors:  J K Eeftinck Schattenkerk; T van Gool; R J van Ketel; J F Bartelsman; C L Kuiken; W J Terpstra; P Reiss
Journal:  Lancet       Date:  1991-04-13       Impact factor: 79.321

5.  Treatment of intestinal microsporidiosis with albendazole in patients with AIDS.

Authors:  C Blanshard; D S Ellis; D G Tovey; S Dowell; B G Gazzard
Journal:  AIDS       Date:  1992-03       Impact factor: 4.177

6.  Intestinal microsporidiosis as a cause of diarrhea in human immunodeficiency virus-infected patients: a report of 20 cases.

Authors:  J M Orenstein; J Chiang; W Steinberg; P D Smith; H Rotterdam; D P Kotler
Journal:  Hum Pathol       Date:  1990-05       Impact factor: 3.466

7.  A microsporidian previously undescribed in humans, infecting enterocytes and macrophages, and associated with diarrhea in an acquired immunodeficiency syndrome patient.

Authors:  J M Orenstein; M Tenner; A Cali; D P Kotler
Journal:  Hum Pathol       Date:  1992-07       Impact factor: 3.466

8.  Chronic microsporidian infection of the nasal mucosae, sinuses and conjunctivae in HIV disease.

Authors:  C J Lacey; A M Clarke; P Fraser; T Metcalfe; G Bonsor; A Curry
Journal:  Genitourin Med       Date:  1992-06

9.  The molecular nature of benzimidazole resistance in helminths.

Authors:  M H Roos
Journal:  Parasitol Today       Date:  1990-04

10.  Pharmacokinetics of albendazole in man.

Authors:  S E Marriner; D L Morris; B Dickson; J A Bogan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more
  9 in total

1.  Enterocytozoon bieneusi in AIDS: symptomatic relief and parasite changes after furazolidone.

Authors:  D Dionisio; L I Manneschi; S Di Lollo; A Orsi; G Sterrantino; M Meli; M Gabbrielli; A Tani; A Papucci; F Leoncini
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

2.  Use of a fluorescent probe to assess the activities of candidate agents against intracellular forms of Encephalitozoon microsporidia.

Authors:  G J Leitch; M Scanlon; A Shaw; G S Visvesvara; S Wallace
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

3.  Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro.

Authors:  E S Didier
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 4.  Molecular techniques for detection, species differentiation, and phylogenetic analysis of microsporidia.

Authors:  C Franzen; A Müller
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

5.  Persistent damage to Enterocytozoon bieneusi, with persistent symptomatic relief, after combined furazolidone and albendazole in AIDS patients.

Authors:  D Dionisio; L I Manneschi; S Di Lollo; A Orsi; G Sterrantino; F Leoncini; M Pozzi; M A Vinattieri; A Tani; A Papucci
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

Review 6.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  Analysis of the beta-tubulin gene and morphological changes of the microsporidium Anncaliia algerae both suggest albendazole sensitivity.

Authors:  Marianita Santiana; Cyrilla Pau; Peter M Takvorian; Ann Cali
Journal:  J Eukaryot Microbiol       Date:  2014-09-15       Impact factor: 3.346

8.  Identification of microsporidia in stool specimens by using PCR and restriction endonucleases.

Authors:  D P Fedorko; N A Nelson; C P Cartwright
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

Review 9.  Therapeutic targets for the treatment of microsporidiosis in humans.

Authors:  Bing Han; Louis M Weiss
Journal:  Expert Opin Ther Targets       Date:  2018-11-01       Impact factor: 6.902

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.